id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
1982474,3055e158-1468-402f-adf1-3fce81115852,Q2,MR. BRIAN KELLY,40024191,LUNDBECK PHARMACEUTICALS,2017,second_quarter,PHA,"CNS
Brain Disorders
Alzheimer's","HOUSE OF REPRESENTATIVES,SENATE",15000,,0,0,2017-06-30T10:55:16.673000-04:00
1982947,1b903b62-5c13-4521-b7fb-9af47ef27b58,Q2,"WELLINGTON STRATEGIES, LLC.",401104410,"OMNICELL, INC.",2017,second_quarter,PHA,Regulations pertaining to the Drug Quality and Security Act (Public Law No: 113-54),"Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",15000,,0,0,2017-07-05T10:01:32.560000-04:00
1983215,c912fff0-ad65-41a4-a27b-30e879858069,Q2,AMERICAN AMBULANCE ASSOCIATION,56018,AMERICAN AMBULANCE ASSOCIATION,2017,second_quarter,PHA,"Lobbied for passage of Protecting Patient Access to Emergency Medication Act (H.R. 304, S. 916).","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",,280000,0,0,2017-07-05T17:00:49.500000-04:00
1983388,55f83551-dc10-499b-87c1-0eb70db2ca35,Q2,AMERICAN COLLEGE OF CLINICAL PHARMACY,57258,AMERICAN COLLEGE OF CLINICAL PHARMACY,2017,second_quarter,PHA,Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs.,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,128375,0,0,2017-07-06T12:18:21.283000-04:00
1983547,ff0bc16d-bc60-4eb9-84aa-ca96dced8007,Q2,INDEPENDENT PHARMACY COOPERATIVE,313098,INDEPENDENT PHARMACY COOPERATIVE,2017,second_quarter,PHA,"Support S. 109/H.R. 592, the Pharmacy and Medically Underserved Areas Enhancement Act
Support S.413/H.R. 1038, the ""Improving Transparency and Accuracy in Medicare Part D Drug Spending Act.
Ensure patient choice in Comprehensive Addiction and Recovery Act of 2016 lock-in provision.
Support Affordable Care Act of 2010 Average Manufacturer Price methodology.","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",,30000,0,0,2017-07-06T15:35:00.467000-04:00
1983548,6f1b8a3c-3ee9-4848-9fd2-89eebac44271,2T,STANTON PARK GROUP,83717,OSH'S NOT FOR PROFIT PHARMACEUTICALS,2017,second_quarter,PHA,information gathering regarding pharmaceutical compounding,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",10000,,0,1,2017-07-06T15:36:01.903000-04:00
1983674,19103d00-b163-411a-ad14-5076c79ec73a,Q2,AMERICAN CAPITOL GROUP,305852,CARDINAL HEALTH,2017,second_quarter,PHA,Issues Related to Distribution and Sale of Pharmaceutical and Medical Products and Services;,"HOUSE OF REPRESENTATIVES,SENATE",25000,,0,0,2017-07-06T17:09:11.363000-04:00
1983682,eabaa3a7-f07d-4638-90b2-36423cf89163,2A,AMERICAN CAPITOL GROUP,305852,CARDINAL HEALTH,2017,second_quarter,PHA,Issues Related to Distribution and Sale of Pharmaceutical and Medical Products and Services;,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",25000,,0,0,2017-07-06T17:16:17.237000-04:00
1983848,9f4a8bef-4022-4d2f-9ac2-f9a636f88622,Q2,AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION,401103437,AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION,2017,second_quarter,PHA,"Determining the intended use of drugs and/or devices and using scientific exchange to share data on ""Off-label use"" (HR 1703/Medical Products Communications Act of 2017)","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2017-07-07T11:45:34.467000-04:00
1984096,1a10336a-f323-4117-a63b-6c7b82af5aee,Q2,PENN AVENUE PARTNERS,400918672,PURDUE PHARMA L.P.,2017,second_quarter,PHA,Monitoring legislative and regulatory activities impacting the pharmaceutical industry.,SENATE,60000,,0,0,2017-07-07T17:50:48.440000-04:00
1984452,28655048-411c-421a-9cbd-0faba9398dd3,Q2,RED+BLUE STRATEGIES,400693064,EXPRESS SCRIPTS INC.,2017,second_quarter,PHA,"S. 637 - Creating Transparency to have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices.


S. 771 - A bill to Improve Access to Affordable Prescription Drugs - Issue related to bringing drug pricing down including better policies in the Part D coverage gap, couponing and advancing biosimilars. 

H.R. 281- National Defense Authorization Act for FY 2018- Issues related to prescription medications for military personnel and their families.","Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2017-07-10T13:37:04.490000-04:00
1984497,d8f34a85-2ea2-4807-ad4e-9fbfc4068fd6,Q2,RED+BLUE STRATEGIES,400693064,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA),2017,second_quarter,PHA,"S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. 

S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars. 

S. 934 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy and delivery. 

H.R. 2430 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy, and delivery. 

Issues related to the price of prescription medications in the United States.","Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",60000,,0,0,2017-07-10T14:04:59.903000-04:00
1984555,fac8943f-589a-4fb2-b2cf-f3e2c2750568,Q2,RED+BLUE STRATEGIES,400693064,PEW CHARITABLE TRUSTS,2017,second_quarter,PHA,"S. 934 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy and delivery. 

H.R. 2430 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy, and delivery. 

S. 1334/H.R. 2797 - Patient Choice and Quality Care Act of 2017 - Issues related to better integration of end-of-life and palliative care into the nation's health care system. 

H.R. 2871 - The Preserving Patient Access to Compounded Medications Act of 2017 - Concerns about how the bill could compromise safety protocols for compounded medications. 

Issues related to antibiotic innovation and advancement.

Issues related opioid abuse and methods to fight against the opioid epidemic in the United States.

Issues related to ensuring the safety of compounded medications. 

Issues related to over the counter medications and supplements. 

Issues related to the Physician Payment Sunshine Act and the Open Payments system.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2017-07-10T14:44:54.160000-04:00
1984603,516364b9-a563-41bd-9cbb-4ed84ba1923b,Q2,WAXMAN STRATEGIES,401103693,340B HEALTH,2017,second_quarter,PHA,Issues affecting the 340B drug pricing program,HOUSE OF REPRESENTATIVES,18750,,0,0,2017-07-10T15:06:35.687000-04:00
1984730,ba828b8b-c3bf-4a76-b728-7cf992e9b8b7,Q2,MCDERMOTT+ LLC,401103287,ALLIANCE FOR RURAL HOSPITAL ACCESS,2017,second_quarter,PHA,Amendments to Section 340B of the Public Health Service Act to gain eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program.,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2017-07-10T17:02:56.340000-04:00
1985239,722bc2a8-684b-4438-9c67-7d2d5cf6122c,Q2,"PD FRAZER CONSULTING, INC.",65998,CANADA INTERNATIONAL PHARMACY ASSOCIATION,2017,second_quarter,PHA,"Support intent of H.R.1480 Safe and Affordable Drugs from Canada Act of 2017
Support intent of S.92 Safe and Affordable Drugs from Canada Act of 2017
Support intent of H.R. Affordable and Safe Prescription Drug Importation Act
Support of S.469 Affordable and Safe Prescription Drug Importation Act","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2017-07-11T15:33:51.513000-04:00
1985756,eb355345-7deb-409b-9383-f8565185f57a,Q2,COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE,11003,COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE,2017,second_quarter,PHA,Oppose S. 637,"HOUSE OF REPRESENTATIVES,SENATE",,70000,0,0,2017-07-12T12:46:36.527000-04:00
1986313,f50d68f0-83bc-45de-8602-167dcb834893,Q2,RUBIN AND RUDMAN LLP,400942719,BLINK HEALTH LTD (A BERMUDA LIMITED COMPANY),2017,second_quarter,PHA,"Advocate for client before members of the U.S. House of Representatives, U.S. Senate, and staffs to each, with respect to market based solutions to drug pricing and chain pharmacy barriers to generic pharmaceutical price reduction.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2017-07-13T10:32:21.423000-04:00
1986601,f9557be6-ef58-4ba9-a51e-0b37f2cbf16e,Q2,RED+BLUE STRATEGIES,400693064,BLUE CROSS BLUE SHIELD OF MASSACHUSETTS,2017,second_quarter,PHA,Issues related to curbing the abuse of opioids in the United States.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2017-07-13T12:32:19.080000-04:00
1986622,7830c1a3-b481-425a-ba64-4874b49489e9,Q2,RED+BLUE STRATEGIES,400693064,COHERUS BIOSCIENCES,2017,second_quarter,PHA,"S. 771 - A bill to improve access to affordable prescription drugs - issues related to ensuring a healthy market for biosimilar medications. 

S.934 - FDA Reauthorization Act of 2017 - All issues related to the development and marketing of biosimilar medications. 

H.R. 2797 - FDA Reauthorization Act of 2017 - All issues related to the development and marketing of biosimilar medications. 

Issues related to the treatment of biosimilar medications in Medicare Part B and D programs. 

Issues related to the maintenance of current IPR laws.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",60000,,0,0,2017-07-13T13:01:35.477000-04:00
1986690,f2027c0a-1de3-4650-a6d2-f915d135bb07,Q2,KATE MOSS,25988,CVS HEALTH,2017,second_quarter,PHA,Legislation impacting PBMs and drug pricing,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2017-07-13T14:10:41.623000-04:00
1986744,ae5411c5-82a2-4423-9f84-da90bfaac33b,Q2,"PARRY, ROMANI, DECONCINI & SYMMS",30792,ROCK & ASSOCIATES,2017,second_quarter,PHA,"Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017.","HOUSE OF REPRESENTATIVES,SENATE",12000,,0,0,2017-07-13T14:49:19.330000-04:00
1986780,b287a294-f7dd-4ccd-a766-a6820adf8cda,Q2,NELSON MULLINS RILEY & SCARBOROUGH,285871,CASCADE HEMOPHILIA CONSORTIUM,2017,second_quarter,PHA,Issues related to 340B Drug Pricing Program,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2017-07-13T15:07:48.780000-04:00
1986789,2148bf11-3e21-4bff-b2dd-7a7272ee9cba,Q2,NELSON MULLINS RILEY & SCARBOROUGH,285871,HEMOPHILIA OF GEORGIA,2017,second_quarter,PHA,Issues related to the 340B Drug Pricing Program and the proposed American Health Care Act,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2017-07-13T15:08:54.140000-04:00
1987935,26d88045-a41a-42d0-b6b2-801894062fdf,Q2,HOLLAND & KNIGHT LLP,18466,THE BIOSIMILARS FORUM,2017,second_quarter,PHA,"Medicare reimbursement issues, FDA regulation of biosimilars;  S. 934, H.R. 2430, the FDA Reauthorization Act of 2017.","Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",120000,,0,0,2017-07-14T15:53:47.137000-04:00
1988011,08a06000-9871-4030-8644-00e6db970845,Q2,MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP),24486,INOVIO PHARMACEUTICALS,2017,second_quarter,PHA,Government Relations Services including developing strategies to achieve legislative goals,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2017-07-14T16:57:55.560000-04:00
1988111,683a2686-d2ac-471c-ad6f-321cd72f36bf,Q2,ROCK & ASSOCIATES,33545,"BRAIDWOOD MANAGEMENT, INC.",2017,second_quarter,PHA,"Issues pertaining to pharmacy compounding.  H.R. 2871, Patient Access to Compounded Medications Act of 2017.","HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2017-07-15T11:05:36.160000-04:00
1988115,3256e429-ce0d-4246-9b64-204ca197d884,Q2,ROCK & ASSOCIATES,33545,DIAMONDBACK DRUGS,2017,second_quarter,PHA,"Legislation pertaining to pharmacy compounding.  H.R. 2871, Patient Access to Compounded Medications Act of 2017.","HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2017-07-15T11:07:38.350000-04:00
1988117,9c310cd0-d52b-4fa0-96f1-bd60a847a632,Q2,ROCK & ASSOCIATES,33545,"VETERINARY PHARMACIES OF AMERICA, INC.",2017,second_quarter,PHA,"Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  H.R. 2871, Patient Access to Compounded Medications Act of 2017.","HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2017-07-15T11:09:40.273000-04:00
1988121,13e638d3-0657-4270-9d50-f49d977f84c7,Q2,ROCK & ASSOCIATES,33545,"WEDGEWOOD VILLAGE PHARMACY, INC.",2017,second_quarter,PHA,"Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  H.R. 2871, Patient Access to Compounded Medications Act of 2017.","HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2017-07-15T11:11:42.307000-04:00
1988124,37443b5d-7728-47df-857b-af71348d9cd4,Q2,ROCK & ASSOCIATES,33545,WOMEN'S INTERNATIONAL PHARMACY,2017,second_quarter,PHA,"Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  H.R. 2871, Patient Access to Compounded Medications Act of 2017.","HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2017-07-15T11:12:43.823000-04:00
1988127,db4f9046-4456-4e2f-b990-5dff779fa1af,Q2,ROCK & ASSOCIATES,33545,WELLNESS PHARMACY,2017,second_quarter,PHA,"Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017.","HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2017-07-15T11:13:47.837000-04:00
1988221,dc2dbf8e-fa53-4676-ba93-811c01f69e26,Q2,THE D MAJOR GROUP,401103162,CVS CAREMARK,2017,second_quarter,PHA,Advocate for the protection of pharmaceutical benefit management and resulting cost savings.,"HOUSE OF REPRESENTATIVES,SENATE",34500,,0,0,2017-07-16T00:18:42.963000-04:00
1988337,fe4331e7-aa07-4397-97c4-355bfbab5975,Q2,BROYDRICK & ASSOCIATES,7268,TONIX PHARMACEUTICALS,2017,second_quarter,PHA,Funding for a new drug for PTSD.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2017-07-16T20:11:08.307000-04:00
1988738,825e21dc-0760-4fcb-b7ce-5eab84c35bec,Q2,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION,31348,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION,2017,second_quarter,PHA,"Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks.  

Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, Direct and Indirect Remuneration (DIR), pharmacy networks, and mail-service pharmacy.  

Issues related to the management of Medicaid prescription drug benefits. 

Issues related to prescription drug abuse.

Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price.  

HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act
H.R.1316, Prescription Drug Price Transparency Act
S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
S.771, Improving Access to Affordable Prescription Drug Act
H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act","Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),SENATE",,763533,0,0,2017-07-17T11:01:45.610000-04:00
1988833,bd4f9eee-3900-4f08-b3e4-24d54addeac4,Q2,NOVO NORDISK INC.,284790,NOVO NORDISK INC.,2017,second_quarter,PHA,Issues related to H.R. 2430/S. 934 FDA Reauthorization Act of 2017 (Prescription Drug User Fee Act VI); H.R. 1245/S. 469 Affordable and Safe Prescription Drug Importation Act; H.R. 1776/S.771 Improving Access To Affordable Prescription Drugs Act; issues related to 340B program,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE",,830000,0,0,2017-07-17T11:30:45.490000-04:00
1988855,3539675f-dcc7-4d3d-a4e8-ff11f0391368,Q2,AMERICAN VETERINARY MEDICAL ASSOCIATION,3630,AMERICAN VETERINARY MEDICAL ASSOCIATION,2017,second_quarter,PHA,"H.R. 623, Fairness to Pet Owners Act
Veterinary Compounding Draft Legislation
Discussions with Congressional staff and FDA to express the need for compounding of medications for use in animals and FDA's draft GFI #230
Discussions with DEA regarding use of controlled substances by veterinary practitioners, transportation of controlled substances, telemedicine and prescription monitoring programs.","Agriculture, Dept of (USDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE",,200000,0,0,2017-07-17T11:31:50.880000-04:00
1988964,2f914476-aead-44f7-a524-1f8e8e28a152,Q2,SQUIRE PATTON BOGGS,30906,BIOTECHNOLOGY INNOVATION ORGANIZATION,2017,second_quarter,PHA,Monitoring legislation that could impact pharmaceutical industry.,"HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2017-07-17T11:56:02.807000-04:00
1989061,22a2a737-9278-478c-8e56-f3d5af8591af,Q2,BUCHANAN INGERSOLL & ROONEY PC,55291,60 DEGREES PHARMACEUTICALS,2017,second_quarter,PHA,Government relations services relating to priority review voucher within the user fee reauthorization legislation.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2017-07-17T12:28:23.137000-04:00
1989151,99461f34-0edf-49ff-bb35-8bb4cbbd0703,Q2,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,AMERICAN SOCIETY OF HEMATOLOGY,2017,second_quarter,PHA,"HR 1409, Cancer Drug Coverage Parity Act","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",30000,,0,0,2017-07-17T13:07:24.303000-04:00
1989156,81917821-edd5-45e4-9813-9b04e81e8a8a,Q2,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,THE HEMOPHILIA ALLIANCE,2017,second_quarter,PHA,Issues related to the 340B drug discount program,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2017-07-17T13:09:25.990000-04:00
1989162,f330ee14-120f-4f0c-80dd-907a2abf7929,Q2,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,NATIONAL HEMOPHILIA FOUNDATION,2017,second_quarter,PHA,"Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing programs.","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",50000,,0,0,2017-07-17T13:10:29.507000-04:00
1989171,608b3b91-7921-416a-bfad-dc09258a4834,Q2,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,NATIONAL ASSOCIATION OF EPILEPSY CENTERS,2017,second_quarter,PHA,Issues related to anti-epileptic drugs.,"Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",10000,,0,0,2017-07-17T13:11:30.647000-04:00
1989282,c94ba27c-4424-40c3-a306-448f97f9fdf4,Q2,SAFEWAY INC.,300173,SAFEWAY,2017,second_quarter,PHA,"H.R. 592, S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions.

H.R. 1038/S. 413  - Improving Transparency and Accuracy in Medicare Part D Spending Act, all provisions.

H.R. 2430 - FDA Reauthorization Act of 2017, amendments related to importation of prescription drugs

Implementation of 2017 NDAA Tricare Pilot.","HOUSE OF REPRESENTATIVES,SENATE",,80000,0,0,2017-07-17T13:51:32.467000-04:00
1989360,58626d71-5430-4907-ac76-1317ed8a34e4,Q2,"ASSOCIATION OF NATIONAL ADVERTISERS, INC.",4653,"ASSOCIATION OF NATIONAL ADVERTISERS, INC.",2017,second_quarter,PHA,Proposals relating to the regulation of direct-to-consumer prescription drug advertising,"Federal Communications Commission (FCC),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE,Treasury, Dept of",,430000,0,0,2017-07-17T14:08:28.857000-04:00
1989589,c67acff4-d2ce-44d9-9a1e-075753262e27,Q2,NATIONAL NURSES UNITED,40021153,NATIONAL NURSES UNITED,2017,second_quarter,PHA,"H.R. 1245 - support for Affordable & Safe Prescription Drug Importation Act

H.R. 1776 - support for Improving Access to Affordable Prescription Drugs Act","HOUSE OF REPRESENTATIVES,SENATE",,50000,0,0,2017-07-17T14:49:07.517000-04:00
1989668,0c5ff2c9-8a96-47b2-b1fe-652508e3ef89,Q2,"MEHLMAN CONSULTING, INC.",284950,VIRTUS PHARMACEUTICALS LLC,2017,second_quarter,PHA,FDA Drug Approval,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2017-07-17T14:59:59.190000-04:00
1989970,a92cea2a-21be-471c-bc80-72a8a9abd472,Q2,NATIONAL ASSOCIATION FOR THE ADVANCEMENT OF COLORED PEOPLE,48975,NATIONAL ASSOCIATION FOR THE ADVANCEMENT OF COLORED PEOPLE,2017,second_quarter,PHA,"Support maintaining ACA Patient Protections and Access to Prescription drugs
Support S. 469 / HR 1245, the Affordable and Safe Prescription Drug Importation Act 
Support Klobuchar Amendment #178 to S. Con. 3 which established a deficit neutral fund relating to lower drug prices for Americans by importing prescription drugs from Canada.
Support Wyden amendment #188 to S Con Res 3 creating a point of order against legislation that does not lower drug prices.","Agriculture, Dept of (USDA),Bureau of Alcohol Tobacco Firearms & Explosives,Centers For Medicare and Medicaid Services (CMS),Consumer Financial Protection Bureau (CFPB),Education, Dept of,Election Assistance Commission (EAC),Environmental Protection Agency (EPA),Equal Employment Opportunity Commission (EEOC),Federal Communications Commission (FCC),Federal Housing Finance Agency (FHFA),Federal Motor Carrier Safety Administration,Federal Reserve System,Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),Justice, Dept of (DOJ),Labor, Dept of (DOL),Natl Park Service (NPS),Office of Management & Budget (OMB),Office of the Comptroller of the Currency (OCC),Securities & Exchange Commission (SEC),SENATE,Social Security Administration (SSA),State, Dept of (DOS),Transportation, Dept of (DOT),Treasury, Dept of,White House Office",,70000,0,0,2017-07-17T15:55:14.230000-04:00
1989985,07ed27e8-7a56-4e95-9374-37487608c696,Q2,AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS,3457,AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS,2017,second_quarter,PHA,"Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Communication with FDA on Generic Drug User Fee Act, Prescription Drug user Fee Act, Biosimilar User Fee Act, and electronic drug information. Contact on manufacturing gaming REMS to gain market advantage and drug importation. Communication with Congress on off-label use. Contact on the 340B program.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE",,270000,0,0,2017-07-17T15:56:23.167000-04:00
1990219,e64d13d8-434e-42c1-9604-00126f78197c,Q2,"POWERS PYLES SUTTER & VERVILLE, P.C.",32008,340B HEALTH,2017,second_quarter,PHA,"Section 340B of the Public Health Services Act, Section 1927 of the Social Security Act and issues related to (1) administration and Congressional oversight of the 340B Drug Discount Program, (2) implementation of 340B-related provisions in the Patient Protection and Affordable Care Act of 2010, and (3)finding of the Health Resources and Services Administration (HRSA) under the Labor Health & Human Services & education appropriations bills.","HOUSE OF REPRESENTATIVES,SENATE",25000,,0,0,2017-07-17T17:02:08.470000-04:00
1990394,db3b05c7-3117-49ac-bcb1-12264a2c50e7,2A,ROCK & ASSOCIATES,33545,PRECISION PHARMACY,2017,second_quarter,PHA,"Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  H.R. 2871, Patient Access to Compounded Medications Act of 2017.","HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2017-07-17T19:03:39.387000-04:00
1990605,37330c5e-d1dc-45ad-bab8-9b01e235e6f8,Q2,DAVE KOLBE CONSULTING,401104329,PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION,2017,second_quarter,PHA,"Medicare Part-D rebates
Trade agreements
Patent reform issues","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2017-07-18T08:49:45.667000-04:00
1990720,961401e7-5ec9-440e-8615-86611f3549ef,Q2,KING & SPALDING LLP,21632,"SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)",2017,second_quarter,PHA,Issues related to inclusion of prescription drugs within Essential Health Benefit and mental health coverage expansion,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2017-07-18T09:51:17.800000-04:00
1990746,06dd84cb-d3f6-4b91-8875-64ffcd0e3e1a,Q2,TRAVERE THERAPEUTICS,401104190,TRAVERE THERAPEUTICS,2017,second_quarter,PHA,"Orphan Drug Act, Drug Quality and Security Act drug safety issues, drug pricing, Prescription Drug User Fee Act reauthorization, FAST Generics and CREATES Acts, FDA issues","HOUSE OF REPRESENTATIVES,SENATE",,140000,0,0,2017-07-18T09:55:26.940000-04:00
1990779,d67c1753-78ec-4e3b-9154-00a8d5c361e4,Q2,HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA),28776,HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA),2017,second_quarter,PHA,"Rx Pedigree (Public Law 113-54); Ensuring Patient Access and Effective Enforcement Act (Public Law 114-145); Prescription Drug Abuse - General issues related to Rx drug abuse; Importation of Prescription Drugs (S 469, S 771, HR 1776, HR 1245, HR 934, HR 1480, S 92, S 64), Implementation of Public Law 113-54 (DSCSA)","Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,302000,0,0,2017-07-18T10:02:47.770000-04:00
1990797,feb402ef-8c59-4d96-b911-f865ae8ddac2,Q2,THORN RUN PARTNERS,400534596,"EXPRESS SCRIPTS, INC.",2017,second_quarter,PHA,"Pharmacy benefits manager standards under the Medicare prescription drug program to further transparency of payment methodologies to pharmacies. Issues related to a pilot program in TRICARE that would establish Department of Defense (DoD) acquisition cost parity for prescription drugs obtained at community pharmacies. Drug reimbursement and general pharmacy related issues. S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017; issues related to transparency of pharmacy benefit managers (PBMs).","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2017-07-18T10:10:00.567000-04:00
1991266,9524e962-b455-4ab3-87a3-061becba9b46,Q2,MASSACHUSETTS MEDICAL SOCIETY,23975,MASSACHUSETTS MEDICAL SOCIETY,2017,second_quarter,PHA,"S. 771 - Improving Access to Affordable Prescription Drugs - Legislation that seeks to address prescription drug costs by increasing transparency and accountability, boosting access and affordability of key drugs, spurring innovation, and increasing choice and competition by allowing Medicare to negotiate the price of drugs, among other provisions.

Efforts to require the manufacturers suggested retail price of prescription drugs in direct to consumer advertising of prescription drugs - no specific bill","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",,70000,0,0,2017-07-18T11:52:31.607000-04:00
1991270,9a636286-5008-4eff-81ad-9193a2ca20ba,Q2,ASCENSION HEALTH,53301,ASCENSION HEALTH,2017,second_quarter,PHA,"Drug pricing; Creating and Restoring Equal Access to Equivalent Samples Act of 2016 (CREATES)
FAIR Drug Pricing Act","Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,248000,0,0,2017-07-18T11:53:34.453000-04:00
1991656,fca37d82-3d97-4fd0-9d2c-92c4260e4d01,Q2,WINNING STRATEGIES WASHINGTON,50796,KALEO,2017,second_quarter,PHA,Pharmaceutical drug development including epinephrine for anaphylaxis,"HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE",30000,,0,0,2017-07-18T13:25:31.510000-04:00
1991684,a7667959-d663-4d46-b9ea-5152afa4cb29,Q2,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,29403,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,2017,second_quarter,PHA,"Pseudoephedrine

Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number).

Oral Contraceptives

H.R. 421/S. 93 - Allowing Greater Access to Safe and Effective Contraception Act of 2017. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-counter) status; all sections.

Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC Switch

Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines.","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of",,215000,0,0,2017-07-18T13:28:45.493000-04:00
1991818,af8b7066-30ba-47ee-92a8-c7a9919e9f3d,Q2,"TARPLIN, DOWNS & YOUNG, LLC",304736,ASTRAZENECA,2017,second_quarter,PHA,"PL 114-255 - 21st Century Cures, implementation
H.R. 2430 - FDA Reauthorization Act of 2017

***, no specific bill(s), Import Safety, drug development policy, drug shortages, supply chain integrity, Innovation, reimportation","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2017-07-18T13:49:12.200000-04:00
1992021,89bddcc8-6b76-4b16-8945-25ada3bd81e6,Q2,BLUECROSS BLUESHIELD OF TENNESSEE,6440,BLUECROSS BLUESHIELD OF TENNESSEE,2017,second_quarter,PHA,General pharmacy and pharmaceutical issues; Opioid Abuse; prescription drug pricing,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,30000,0,0,2017-07-18T14:21:50.610000-04:00
1992114,a0d66aa1-63d0-4e8b-a168-d34ddd1e1de8,Q2,"ALKERMES, INC.",400458235,"ALKERMES, INC.",2017,second_quarter,PHA,"Public law #114-198, Cures Opioid Funding Implementation 
H.R. 2430 FDA Reauthorization Act of 2017
S.934 FDA Reauthorization Act of 2017","Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA),Veterans Affairs, Dept of (VA)",,940000,0,0,2017-07-18T14:36:56.847000-04:00
1992566,dfe7601c-16b4-4581-b2ff-33dc62ba7612,Q2,FOLEY & LARDNER LLP,15042,"ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY",2017,second_quarter,PHA,FDA issues; Issues relating to prescription drug abuse; Issues relating to CDC guidance for prescribing opioids; Issues relating to removal of FDA unapproved products from the market.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2017-07-18T15:21:27.040000-04:00
1992671,72dee276-628d-479d-9154-c785ed14cc83,Q2,AMERICAN PHARMACISTS ASSOCIATION,3071,AMERICAN PHARMACISTS ASSOCIATION,2017,second_quarter,PHA,"HR 1038, S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act
HR 1939 To amend title XVIII of the Social Security Act to ensure equal access of Medicare beneficiaries to community pharmacies in underserved areas as network pharmacies under Medicare prescription drug coverage, and for other purposes.
HR 592, S 109 To amend title XVIII of the Social Security Act to provide for coverage under the Medicare program of pharmacist services.
HR 1480 Safe and Affordable Drugs from Canada Act of 2017
S 637 Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
HR 1586 To amend the Federal Food, Drug, and Cosmetic Act to ensure that liquid over-the-counter medications are packaged with appropriate dosage delivery devices and, in the case of such medications labeled for pediatric use, appropriate flow restrictors, and for other purposes.
S 778 Prescription Drug Monitoring Act of 2017
HR 934 Personal Drug Importation Fairness Act of 2017
HR 421 Allowing Greater Access to Safe and Effective Contraception Act
HR 1436 To provide for reconciliation pursuant to title II of the concurrent resolution on the budget for fiscal year 2017.
HR 1245, S 469 To amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals.
HR 3268 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018 (drug compounding provisions)
S 1079 Protecting Americans from Dangerous Opioids Act 
HR 2430 FDA Reauthorization Act of 2017
HR 2567 Access to Birth Control Act 
HR 2871 Preserving Patient Access to Compounded Medications Act of 2017
HR 2063 Opioid PACE Act of 2017
S 1003 A bill to amend title XIX of the Social Security Act to add standards for drug compendia for physician use for purposes of Medicaid payment for certain drugs, and for other purposes
HR 1939/S 1044 Ensuring Seniors Access to Local Pharmacies Act of 2017","HOUSE OF REPRESENTATIVES,SENATE",,30000,0,0,2017-07-18T15:34:41.917000-04:00
1992834,4b9bccfb-b50c-4530-9879-d86b6b192fe1,Q2,FOLEY & LARDNER LLP,15042,PAR PHARMACEUTICAL,2017,second_quarter,PHA,FDA issues,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2017-07-18T15:55:44.480000-04:00
1992918,bac11409-b276-42ef-a9fe-c6f7dc327de4,Q2,"CARD & ASSOCIATES, LLC",84217,AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY),2017,second_quarter,PHA,"Educate Members on pharmacy contracting with pharmacy benefit managers
H.R. 1316 Prescription Drug Price Transparency Act
S. 637 Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017","HOUSE OF REPRESENTATIVES,SENATE",45000,,0,0,2017-07-18T16:07:37.607000-04:00
1993193,891f5c91-ec63-4856-8e0d-9002d12a3f20,Q2,GREATER NEW YORK HOSPITAL ASSOCIATION,16830,GREATER NEW YORK HOSPITAL ASSOCIATION,2017,second_quarter,PHA,"Preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; educating policymakers on hospital drug shortages and significant drug price increases. 

Support drug pricing legislation that would promote competition by fast tracking generic drug applications (H.R. 749/S.297).

Oppose legislation that would harm the 340B drug discount program for safety net hospitals.","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA),White House Office",,540000,0,0,2017-07-18T16:39:13.110000-04:00
1993201,b0fe8814-d1cb-424e-a246-a3463fd21771,Q2,SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING,35968,SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING,2017,second_quarter,PHA,Compounding of radiopharmaceuticals.,"Centers For Medicare and Medicaid Services (CMS),Energy, Dept of,Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Nuclear Regulatory Commission (NRC),Office of Science & Technology Policy (OSTP),SENATE",,50000,0,0,2017-07-18T16:40:15.720000-04:00
1993351,c0feb6ac-cee5-45d0-bc59-d85bc8ba1ad2,Q2,ACADEMY OF MANAGED CARE PHARMACY,48793,ACADEMY OF MANAGED CARE PHARMACY,2017,second_quarter,PHA,"Letters of support for the CREATES Act (H.R. 2212 and S. 974), the FAST Act (H.R. 2051) and the Pharmaceutical Information Exchange Act(H.R. 2026). Comments to FDA on biosimilars and interchangeability,","Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,70000,0,0,2017-07-18T17:08:57.550000-04:00
1993366,9bbad209-3533-4955-bffc-b136bfcc8721,Q2,"TARPLIN, DOWNS & YOUNG, LLC",304736,PHRMA,2017,second_quarter,PHA,"PL 114-255 - 21st Century Cures, implementation
H.R. 1628 - American Health Care Act of 2017

***, no specific bill(s), prescription drug importation, import safety, supply chain integrity, Prescription Drug User Fee Act Fee Reauthorization and associated policies, user fee sequester, innovation","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2017-07-18T17:13:04.803000-04:00
1993398,1f58811f-1516-40e0-91d8-e8049aa3de50,Q2,PRIME THERAPEUTICS,400339576,PRIME THERAPEUTICS,2017,second_quarter,PHA,"H.R.2430/S.934: FDA Reauthorization Act of 2017--provisions to ensure greater market competition for generics & biosimilars. S.469/H.R.1245: Affordable and Safe Prescription Drug Importation Act --issues relating to noninterference and workability. S.778: Prescription Drug Monitoring Act--issues related to dispensers access to PDMP data across state lines. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--Provisions limiting payers' ability to selectively contract. Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums. S.1003: To amend title XIX of the Social Security Act to add standards for drug compendia for physician use for purposes of Medicaid payment for certain drugs, and for other purposes; provisions related do drug coverage in Medicare and Medicaid. H.R.1703: Medical Product Communications Act of 2017--provisions relating to greater market access for off-label indications.","HOUSE OF REPRESENTATIVES,SENATE",,50000,0,0,2017-07-18T17:24:28.943000-04:00
1993426,285785fa-2a22-4c14-8566-d39c971e118d,Q2,THE INGRAM GROUP LLC,400577737,ELI LILLY AND COMPANY,2017,second_quarter,PHA,"General issues related to the biopharmaceutical and pharmaceutical industries including drug importation. H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2017-07-18T17:32:50.617000-04:00
1993445,b90e200b-d219-4003-896a-b4a08e5d399e,Q2,APOTEX CORP.,310973,APOTEX CORP.,2017,second_quarter,PHA,"HR 2430, the FDA Reauthorization Act of 2017, Title VIII, Improving Generic Drug Access, provisions relating to enhancing the generic drug approval process, spurring the development and approval of generic versions of drugs with limited competition, and generic drug exclusivity; 

S. 934, the FDA Reauthorization Act of 2017, Title IX, Generic Drug Access, provisions relating to enhancing the generic drug approval process and spurring the development and approval of generic versions of drugs with limited competition;

HR 2212, the Creating and Restoring Equal Access to Equivalent Samples Act of 2017, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing, and for shared Risk Evaluation and Mitigation (REMS) programs for brand and generic pharmaceuticals;

S. 974, the Creating and Restoring Equal Access to Equivalent Samples Act of 2017, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing, and for shared Risk Evaluation and Mitigation (REMS) programs for brand and generic pharmaceuticals;

HR 2051, the Fair Access for Safe and Timely Generic Act of 2017, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing, and for shared Risk Evaluation and Mitigation (REMS) programs for brand and generic pharmaceuticals; and

Federal policy related to repealing Section 603, Applying the Medicaid additional rebate requirement to generics, of Public Law No 114-67, the Bipartisan Budget Act of 2015","HOUSE OF REPRESENTATIVES,SENATE",,300000,0,0,2017-07-18T17:40:11.930000-04:00
1993454,097532e5-4a24-4429-ba9a-fb1e7bfe6d3a,Q2,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,2017,second_quarter,PHA,"General issues related to over the counter pharmaceuticals, cosmetics issues related to Rx/OTC transition issues related to draft legislation addressing the over the counter drug monograph process, and H. R. 2430, the FDA Reauthorization Act (FDARA) of 2017.","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2017-07-18T17:42:18.900000-04:00
1993683,611ad2ac-40b8-4c3a-895d-37ba60d40382,Q2,THORSEN FRENCH ADVOCACY LLC,400599826,"CARDINAL HEALTH, INC.",2017,second_quarter,PHA,"Issues related to prescription drug abuse.
Issues related to pharmaceutical market value.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2017-07-18T20:40:59.220000-04:00
1993700,955aa0d7-bd72-43c8-a5e5-451b4c00499f,Q2,THORSEN FRENCH ADVOCACY LLC,400599826,HEALTHCARE DISTRIBUTION ALLIANCE,2017,second_quarter,PHA,"General issues related to prescription drug abuse.
Issues related to pharmaceutical market value. 
Prescription drug importation.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2017-07-18T20:54:12.327000-04:00
1993710,96d07d94-e754-4d6b-93aa-d55d04f963ff,Q2,THORSEN FRENCH ADVOCACY LLC,400599826,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA,2017,second_quarter,PHA,"Issues related to pharmaceutical market value.
Issues related to prescription drug abuse.
H.R.2212: CREATES Act of 2017.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2017-07-18T21:01:22.767000-04:00
1993835,cf66dd7b-4193-4c3b-aad9-e8ec94cfa540,Q2,"DAIICHI SANKYO, INC.",316731,DAIICHI SANKYO INC,2017,second_quarter,PHA,"H.R.2025, Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
H.R.2430 and S.934, FDA Reauthorization Act of 2017",HOUSE OF REPRESENTATIVES,,150000,0,0,2017-07-18T23:39:05.707000-04:00
1994385,8667f447-e336-400c-b408-f3efe7bc0eef,Q2,ANIMAL HEALTH INSTITUTE,4037,ANIMAL HEALTH INSTITUTE,2017,second_quarter,PHA,Issues related to illegal drug manufacturing under the guise of pharmacy compounding; Issues related to the granting of Categorical Exclusions for animal health products.,"Agriculture, Dept of (USDA),HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR)",,35000,0,0,2017-07-19T09:45:19.420000-04:00
1994566,030a4f97-e7a9-4db6-9177-e55b11420a48,2A,TRAVERE THERAPEUTICS,401104190,TRAVERE THERAPEUTICS,2017,second_quarter,PHA,"Orphan Drug Act, Drug Quality and Security Act drug safety issues, drug pricing, Prescription Drug User Fee Act reauthorization, FAST Generics and CREATES Acts, FDA issues","HOUSE OF REPRESENTATIVES,SENATE",,170000,0,0,2017-07-19T10:19:20.580000-04:00
1994921,dc95950d-8027-43bc-9ddf-b917ef1e2801,Q2,BUCHANAN INGERSOLL & ROONEY PC,55291,"WOMEN'S CHOICE PHARMACEUTICALS, LLC",2017,second_quarter,PHA,Development of government relations strategy relating to prenatal dietary supplements.,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2017-07-19T11:00:03.663000-04:00
1994925,b1f5e704-50cd-4740-901e-a3d798fb6de1,Q2,AVENUE SOLUTIONS,72111,"JAZZ PHARMACEUTICALS, INC.",2017,second_quarter,PHA,"S. 974, Creating and Restoring Equal Access to Equivalent Samples Act of 2017 (CREATES Act of 2017);
H.R. 2051, FAST Generics Act","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2017-07-19T11:01:06.270000-04:00
1995124,b5860689-908c-40d3-85eb-941e77cd48c8,Q2,UNIVERSITY OF IOWA,49191,UNIVERSITY OF IOWA,2017,second_quarter,PHA,"FY 17 and FY 18 appropriations for NIH
Support for palliative care programs
Support for 340B program","Administration for Children & Families (ACF),Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Education, Dept of,Energy, Dept of,Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),Transportation, Dept of (DOT)",,86662,0,0,2017-07-19T11:19:05.057000-04:00
1995302,2de028ac-bd06-4984-89c3-c46acdbd25a9,Q2,FTI GOVERNMENT AFFAIRS,401054971,PROFESSIONAL COMPOUNDING CENTERS OF AMERICA,2017,second_quarter,PHA,"Implementation of The Drug Quality and Security Act, H.R.3204 (Public Law) ((USP/NF Monograph)). Monitor H.R.2871 ""Preserving Patient Access to Compounded Medication Act of 2017. ""","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2017-07-19T11:33:56.120000-04:00
1995338,5860dfdd-0550-458b-9e62-04c9f9a2cf45,Q2,SC PARTNERS LLC,318994,"PFIZER, INC.",2017,second_quarter,PHA,"Advocated for maintaining a safe prescription drug supply, and shared concerns about the safety and economic implications of allowing the importation of prescription drugs and biologics from Canada and other countries. 

Affordable and Safe Prescription Drug Importation Act (S. 469)","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2017-07-19T11:36:26.087000-04:00
1995445,8e4ec86f-5955-4484-87cc-f57ea25b290c,Q2,"TARPLIN, DOWNS & YOUNG, LLC",304736,BIOTECHNOLOGY INDUSTRY ORGANIZATION,2017,second_quarter,PHA,"PL 114-255 - 21st Century Cures, implementation
H.R. 2430 - FDA Reauthorization Act of 2017


***, no specific bill(s), Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, PDUFA and associated policies, patent settlements, accelerated approval, break through therapies, compounding, user fee reauthorization, Innovation","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",80000,,0,0,2017-07-19T11:46:43.857000-04:00
1995670,d74eca28-9b5a-436d-a4ac-b621f9e437fb,Q2,MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE),400265214,MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE),2017,second_quarter,PHA,"Pricing, shortages, and safety issues","Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",,137625,0,0,2017-07-19T12:14:16-04:00
1995725,91b075d2-d59d-4f83-ab2a-9599cdebf2c8,Q2,FORGE FEDERAL AFFAIRS LLC,400865535,LILLY USA LLC,2017,second_quarter,PHA,"Issues related to pricing of prescription drugs. 
Opposition to prescription drug importation. 
Support for funding of Department of Homeland Security drug interdiction efforts. 
Issues related to reauthorization of the Prescription Drug User Fee Act. 
H.R.2430/S.934, FDA Reauthorization Act of 2017.","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2017-07-19T12:19:53.483000-04:00
1995868,29b88846-1f22-450d-96a4-bc0671976bef,Q2,AMERICAN ASSOCIATION FOR JUSTICE,4733,AMERICAN ASSOCIATION FOR JUSTICE,2017,second_quarter,PHA,"S. 204/H.R. 878 (Trickett Wendler Right to Try Act of 2017); authorizes the use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law.

S. 469/H.R. 1245 (Affordable and Safe Prescription Drug Importation Act); amends the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors.

S. 670/H.R. 1652 (Over-the-Counter Hearing Aid Act of 2017); provides for the regulation of over-the-counter hearing aids.

S. 297/H.R. 749 (Increasing Competition in Pharmaceuticals Act/Lower Drug Costs through Competition Act); amends the Federal Food, Drug, and Cosmetic Act to revise provisions regarding review and approval of generic drug applications or supplements to generic drug applications for drugs in some circumstances.

General Lobbying with regard to the preemption of states causes of action involving medical device and drug manufacturers.

General lobbying with regard to off label promotion of pharmaceutical products.

General lobbying with regard to pharmaceutical drug advertising.

General lobbying with regard to pharmaceutical price-gouging.

Lobbying with regard to biosimilar naming and labeling.

Lobbying with regard to updating generic drug labeling responsibilities.","Consumer Financial Protection Bureau (CFPB),HOUSE OF REPRESENTATIVES,SENATE",,1940000,0,0,2017-07-19T12:36:24.143000-04:00
1996113,582b708e-eb7c-4f45-9855-6ab929cafb31,Q2,"MERCURY PUBLIC AFFAIRS, LLC",70175,KALISPELL REGIONAL HEALTHCARE,2017,second_quarter,PHA,Veteran pharmacy issues and polices,"Federal Communications Commission (FCC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)",30000,,0,0,2017-07-19T13:15:02.663000-04:00
1996301,6c606795-50f4-4ab0-9395-23ec8e4365a4,Q2,BUCHANAN INGERSOLL & ROONEY PC,55291,TONIX PHARMACEUTICALS HOLDING CORP.,2017,second_quarter,PHA,Federal funding related to clinical trials for military PTSD; FY 2018 NDAA and Defense Appropriations,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2017-07-19T13:30:43.243000-04:00
1996492,4cd9c9d2-c6f6-4286-b5ea-56a089243e18,Q2,"TARPLIN, DOWNS & YOUNG, LLC",304736,HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.),2017,second_quarter,PHA,"Importation of prescription drugs (S. 469, S. 771, H.R. 1776, H.R. 1245, H.R. 934, H.R. 1480, S. 92, S. 64)
Rx Pedigree (PL 113-54)
Prescription Drug Monitoring Programs (S. 480, H.R. 1725)
Prescription Drug Abuse - General issues related to Rx drug abuse 
Ensuring Patient Access and Effective Enforcement Act (PL 114-145)
Implementation of Public Law 113-54 (DSCSA)","Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2017-07-19T13:46:40.697000-04:00
1996606,5bbd7163-7bea-43db-8ec9-befede69e9d0,Q2,ELI LILLY AND COMPANY,13392,ELI LILLY AND COMPANY,2017,second_quarter,PHA,Hospital discounts; 340B program,"Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)",,2020000,0,0,2017-07-19T13:52:38.417000-04:00
1996981,cdf58f4d-4226-4a04-8106-dd799a90c9d9,Q2,OREGON HEALTH & SCIENCE UNIVERSITY,30291,OREGON HEALTH & SCIENCE UNIVERSITY,2017,second_quarter,PHA,340b Drug Discount Program for safety net hospitals and Health Resources and Services Administration proposed omnibus guidance.,"HOUSE OF REPRESENTATIVES,SENATE",,70000,0,0,2017-07-19T14:18:07.810000-04:00
1997180,fb352986-5f32-4e7d-b839-dae15aabe954,Q2,BLUE CROSS AND BLUE SHIELD ASSOCIATION,6358,BLUE CROSS AND BLUE SHIELD ASSOCIATION,2017,second_quarter,PHA,"Opioid Abuse; Drug Pricing; 

HR 2026 Pharmaceutical Information Exchange Act Introduced April 6, 2017 by Brett Guthrie (R-VA) To improve patient access to emerging medication therapies by clarifying the scope of permitted health care economic and scientific information communications between biopharmaceutical manufacturers and population health decision makers.

HR 2051 FAST Generics Act Introduced April 6, 2017 by David McKinley (R-WV) To amend the Federal Food, Drug, and Cosmetic Act to ensure that eligible product developers have competitive access to approved drugs and licensed biological products,so as to enable eligible product developers to develop and test new products, and for other purposes.","Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,Treasury, Dept of,Vice President of the U.S.,White House Office",,2050000,0,0,2017-07-19T14:29:41.343000-04:00
1997391,98a5e82d-c709-4551-a8b3-7c92f9ac2280,Q2,AVENUE SOLUTIONS,72111,"MOMENTA PHARMACEUTICALS, INC.",2017,second_quarter,PHA,Improving access to biogenerics,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2017-07-19T14:51:18.890000-04:00
1997477,8fbd6145-9eb3-45b2-9afb-98ea2514df95,Q2,"POLITICAL CAPITAL, LLC",401104260,MEDISCA INC,2017,second_quarter,PHA,"DQSA
Oversight
HR  2871","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",15000,,0,0,2017-07-19T14:56:13.337000-04:00
1997487,5b715d12-485d-415a-9e67-fc942ffa8e5f,Q2,AVENUE SOLUTIONS,72111,CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM,2017,second_quarter,PHA,Issues related to biosimilars,SENATE,80000,,0,0,2017-07-19T14:57:19.853000-04:00
1997655,5cdc3531-6963-45e6-a0d5-e3c5a3f8c876,Q2,ARMORY HILL ADVOCATES (FORMERLY KNOWN AS RAWLSON POLICY GROUP),400637926,ACCREDITATION COMMISSION FOR HEALTH CARE,2017,second_quarter,PHA,Legislation & regulations impacting Pharmacy Compounding.,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",5000,,0,0,2017-07-19T15:08:13.683000-04:00